Polar Capital Holdings Plc Sells 7,884 Shares of Hologic, Inc. (NASDAQ:HOLX)

Polar Capital Holdings Plc cut its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 30.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,009 shares of the medical equipment provider's stock after selling 7,884 shares during the period. Polar Capital Holdings Plc's holdings in Hologic were worth $1,298,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Smithfield Trust Co lifted its position in shares of Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 400 shares in the last quarter. Finally, Sound Income Strategies LLC acquired a new position in shares of Hologic during the fourth quarter worth approximately $60,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director now owns 5,445 shares in the company, valued at $300,781.80. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent research reports. Citigroup dropped their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Morgan Stanley dropped their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Evercore ISI lowered their target price on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. William Blair reaffirmed an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Finally, Leerink Partners downgraded shares of Hologic from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Hologic presently has a consensus rating of "Hold" and an average target price of $77.42.

Hologic Stock Performance

Hologic stock traded up $0.04 during midday trading on Tuesday, reaching $56.47. 1,897,863 shares of the company's stock were exchanged, compared to its average volume of 2,128,179. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock's 50-day simple moving average is $58.67 and its 200 day simple moving average is $67.14. The firm has a market cap of $12.58 billion, a price-to-earnings ratio of 17.81, a P/E/G ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.03 EPS. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.